A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel inBRCA1/2metastatic breast cancer: design and rationale

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

(2016) Hope S. Rugo et al.   NEW ENGLAND JOURNAL OF MEDICINE

102PD * A RANDOMIZED, DOUBLE-BLIND, PHASE 2 TRIAL OF VELIPARIB (ABT-888) WITH CARBOPLATIN AND PACLITAXEL IN PREVIOUSLY UNTREATED METASTATIC OR ADVANCED NON-SMALL CELL LUNG CANCER

(2015) J. Mazieres et al.   ANNALS OF ONCOLOGY

PARP inhibitors in the management of breast cancer: current data and future prospects

(2015) Luca Livraghi et al.   BMC Medicine

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study

(2015) Robert L. Coleman et al.   GYNECOLOGIC ONCOLOGY

Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).

(2015) Shalu Pahuja et al.   JOURNAL OF CLINICAL ONCOLOGY

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

(2015) Steven J. Isakoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

(2015) T. A. Hopkins et al.   MOLECULAR CANCER RESEARCH

Profile of veliparib and its potential in the treatment of solid tumors

(2015) Lars Wagner   OncoTargets and Therapy

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

(2014) F. Cardoso et al.   BREAST

Protein ADP-ribosylation and the cellular response to DNA strand breaks

(2014) K.W. Caldecott   DNA REPAIR

Poly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3

(2014) Carole Beck et al.   EXPERIMENTAL CELL RESEARCH

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

Targeting the DNA Repair Pathway in Ewing Sarcoma

(2014) Elizabeth Stewart et al.   Cell Reports

Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?

(2013) Peter Bouwman et al.   CLINICAL CANCER RESEARCH

The recognition and removal of cellular poly(ADP-ribose) signals

(2013) Eva Barkauskaite et al.   FEBS Journal

Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond

(2013) Nicola J. Curtin et al.   MOLECULAR ASPECTS OF MEDICINE

Structural biology of the writers, readers, and erasers in mono- and poly(ADP-ribose) mediated signaling

(2013) Tobias Karlberg et al.   MOLECULAR ASPECTS OF MEDICINE

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art

(2012) Mike De Vos et al.   BIOCHEMICAL PHARMACOLOGY

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Role of PARP Inhibitors in Cancer Biology and Therapy

(2012) D. Davar et al.   CURRENT MEDICINAL CHEMISTRY

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

(2012) Louise J Barber et al.   JOURNAL OF PATHOLOGY

PARP inhibitors attenuate chemotherapy-induced painful neuropathy

(2012) Jill-Desiree Brederson et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors

(2009) J. P. Palma et al.   CLINICAL CANCER RESEARCH

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

(2009) Shivaani Kummar et al.   JOURNAL OF CLINICAL ONCOLOGY

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

(2009) X. Liu et al.   MOLECULAR CANCER RESEARCH

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hereditary breast cancer: new genetic developments, new therapeutic avenues

(2008) Philippe M. Campeau et al.   HUMAN GENETICS

Chemotherapy-induced neuropathy

(2008) Anthony J. Windebank et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM